Reviva Pharmaceuticals Secures USPTO Priority Examination for Brilaroxazine

Reviva Pharmaceuticals has positioned a new brilaroxazine formulation at the center of its NDA strategy for schizophrenia, with USPTO Track 1 priority examination granted for the composition of matter patent application, a filing that, if successful, could extend exclusivity through 2046 and materially compress the planning window for generic manufacturers.

The formulation change carries direct regulatory consequence. Reviva is awaiting FDA feedback in Q4 2026 on the proposed use of this formulation in the RECOVER-2 registrational Phase 3 trial and a future NDA submission under 21 CFR Part 314. A bridging bioequivalence study to confirm comparability with the earlier formulation is targeted for Q1 2027, a prerequisite step before enrollment can proceed and one that will require robust analytical method validation and reference standard alignment.

Patient enrollment in RECOVER-2 is targeted for the first half of 2027, though Reviva has conditioned that milestone on receipt of additional financing. For CMC and regulatory affairs teams tracking the program, the financing dependency introduces schedule risk that sits upstream of any site activation or IND amendment activity.

On the financial side, Reviva reported a net loss of approximately $2.3 million for Q3 2026, down from $4.0 million in Q3 2025. Cash and cash equivalents stood at $17.5 million as of September 30, 2026, compared to $14.4 million at year-end 2025, a position the company describes as supporting disciplined capital management through the next clinical phase.

The Track 1 pathway, which the USPTO targets for examination completion within approximately 12 months of prioritization, accelerates the timeline to a patentability determination. For NDA planning purposes, the outcome of that examination will influence the patent term data submitted at filing and the subsequent listing in the Orange Book, factors that generic applicants will need to account for in any Paragraph IV certification strategy.

The FDA's Q4 2026 response on the proposed formulation will set the scope of the bioequivalence study and define the CMC package requirements for RECOVER-2, making it the near-term checkpoint that determines whether the 1H 2027 enrollment target remains achievable.

Source: Reviva Pharmaceuticals via GlobeNewswire, November 12, 2026.